Abstract: Objective To compare the clinical safety of sirolimus-eluting stent(SES) and other coronary stents in treating coronary artery disease. MethodsAll comparision study relating to the endpoints of SES in treating coronary artery disease published in the last five years, including major adverse cardiac events(MACE), target vessel revascularization(TVR), target lesion revascularization(TLR), are retrieved by indexing pubmed, OVID medline,sciencedirect, CNKI and Wanfang Data. ResultsCompared to bare-metal stent(BMS), the MACE of SES decreased obviously, at the same time TVR and TLR of SES dropped in significantly too. Contrasting to other drug-eluting stents, the clinical safety of SES was equal to PES, and better than ZES in some patients who had complications of diabetes mellitus or coronary bifurcation lesions. For patients with renal inadequacy, the clinical safety of SES was better than BMS and equal to PES. Perhaps C-reactive protein had a predictive value of the MACE incidence after SES implantation. ConclusionCompared to BMS, SES preferred to show a significantly higher safety which equals to PES.

Key words: sirolimus-eluting stent, bare-metal stent, paclitaxel-eluting stent, zotarolimus-eluting stents, major adverse cardiac events, target vessel revascularization, target lesion revascularization